Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma
DURHAM, N.C., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ®…
Precision BioSciences to Present at Upcoming Virtual Investor Conferences in September
DURHAM, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ®…
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy
DURHAM, N.C., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ®…
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update
Dosed First Patient in Phase 1/2a Clinical Trial of PBCAR269A, a BCMA-Targeted Allogeneic CAR T Candidate for Multiple Myeloma PBCAR0191 and PBCAR20A Clinical Studies Progressing; Updated Interim…
Elo Life Systems Announces Strategic Partnership with Dole Food Company with the Goal of Saving the Cavendish Banana
Fusarium wilt TR4 threatens the $25 billion banana industry without a cure or remedy on the horizon DURHAM, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Elo Life Systems, a food and agriculture company…
Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor Conferences
DURHAM, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®…
Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program
DURHAM, N.C., July 06, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS ®…
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma
-PBCAR269A Targets BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma and is the Company’s Third Investigational Allogeneic CAR T Candidate Advanced to the Clinic – -PBCAR269A is the…
CAR T Explainer
What do frozen samurai warriors and magic goggles have to do with treating cancer? Join Precision BioSciences Chief Science Officer Derek Jantz on a journey into the future of cancer therapies and…
ASH Poster 2019
Initial findings of the Phase 1 trial of PBCAR0191 Presenter: Bijal Shah, MD, Moffitt Cancer Center Session: 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin…
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate
-Preliminary data from ongoing Phase 1/2a trial of PBCAR0191 for the treatment of relapsed/refractory non-Hodgkin lymphoma or relapsed/refractory B-cell precursor acute lymphoblastic leukemia-…
Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial
DURHAM, North Carolina, USA, Nov 12, 2019 – Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a genome editing company dedicated to improving life through the application of its pioneering,…